RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo before transplant may stop blood cancer return
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:27 UTC
-
New combo therapy aims to beat relapsed blood cancers
Disease control Recruiting nowThis study is for adults with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatment. Participants receive a strong chemotherapy combination (CLAG-M or FLAG-Ida) followed immediately by a stem cell transplant from a donor. T…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study tests a combination of three drugs (azacitidine, venetoclax, and gilteritinib) in people with certain blood cancers that have a FLT3 mutation. The goal is to find the safest dose and see if the combo works better than standard treatments. The study includes adults whos…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
Experimental drug combo offers hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial is for people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) whose cancer came back or didn't respond to standard therapy. The study tests a chemotherapy drug combo called CPX-351 to find the safest dose and see if …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:47 UTC
-
New hope for blood cancer patients: canakinumab trial opens
Disease control Recruiting nowThis study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). The drug is an antibody that may slow cancer growth. About 76 adults will receive injections to see if it improves blood c…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new daily pill, onvansertib, for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard therapies. The main goals are to find the safest dose and see if the drug can shrink or…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC